Cerebral Small Vessel Disease Registry Study

NCT04318119 | Recruiting

• 1 other identifier: MRCTA,ECFAH of FMU [2019]245
• Study Type: observational
• Target: 3,000
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this study is to determine the clinical spectrum and natural progression of Cerebral Small Vessel Disease (CSVD) and in a prospective multicenter study, to assess the clinical, genetic and epigenetic features of patients with CSVD, , to find independent imaging markers, and to optimize clinical management.

Conditions

Cerebral Small Vessel Diseases

Outcome Measures

Primary Outcomes (1)

• Overall outcomes in patients with cerebral small vessel disease.

  record the occurrence of stroke and use modified Rankin Scale (mRS) to measure the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability.

  From date of enrollment until the date of death from any cause, assessed up to 30 years

Secondary Outcomes (4)

• the development of the burden of microbleeds in MRI

  From date of enrollment until the date of death from any cause, assessed up to 30 years

• the development of the burden of white matter hypertension in MRI

  From date of enrollment until the date of death from any cause, assessed up to 30 years

• the development of lacunes in MRI

  From date of enrollment until the date of death from any cause, assessed up to 30 years

• the development of enlarged perivascular space in MRI

  From date of enrollment until the date of death from any cause, assessed up to 30 years

Eligibility Criteria

• Age: 18 Years - 100 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patient who are diagnosed as Cerebral Small Vessel Disease

You may qualify if:

• Sign informed consent.
• Age\>18
• At least one of the following CSVD MRI characteristics: ①recent small subcortical infarct;②lacune of presumed vascular origin;③white matter hypertensity of presumed vascular origin;④perivascular space;⑤cerebral microbleeds;⑥brain atrophy

You may not qualify if:

• Unable to cooperate with inspectors
• Non-vascular white matter lesions
• Other cognitive diseases (such as alzheimer's disease, Parkinson's disease or thyroid disease)
• Serious systemic illness, such as heart, liver, kidney disease or major mental illness
• Contraindications for imaging examination

Sponsors & Collaborators

• Bin Cai: lead

Study Sites (1)

Department of Neurology , First Affiliated Hospital Fujian Medical University

Fuzhou, Fujian, 350004, China

RECRUITING

Related Publications (1)

• Hu F, Xie W, Fan M, Wang Y, Xu S, Qiu W, Yang T, Lv H, Huang H, Wu Y, Fu Y, Cai B. Intracerebral Hemorrhage in Autosomal Dominant Cerebral Arteriopathy With Subcortical Infarcts and Leukoencephalopathy. Eur J Neurol. 2025 Mar;32(3):e70100. doi: 10.1111/ene.70100.

  PMID: 40067051 DERIVED

MeSH Terms

Conditions

Cerebral Small Vessel Diseases

Condition Hierarchy (Ancestors)

Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases

Central Study Contacts

Bin Cai, PhD

CONTACT

13338413842; caibin929@163.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 30 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: March 14, 2020
• First Posted: March 23, 2020
• Study Start: November 18, 2019
• Primary Completion (Estimated): November 18, 2049
• Study Completion (Estimated): November 18, 2055
• Last Updated: September 28, 2023

Record last verified: 2023-09

Locations

CN (1)